NANOPHASE TECHS CORP - NANX STOCK NEWS

Nanophase Technologies Corporation (NANX) reported a record 70% year-over-year revenue growth, totaling $29.5 million for 2021. Solésence revenue soared by 170%, while Active Pharmaceutical Ingredients (API) sales grew by 40%. Despite these gains, the company faced operational challenges, including labor shortages and supply chain issues, which affected Q4 profitability. The company is focused on expanding its infrastructure to handle increased demand, recently leasing a new 260,000 sq. ft. facility. Expectations for Q1 2022 revenue are above $7 million, with ongoing partnerships and product launches.

Nanophase Technologies Corporation (OTCQB: NANX) announced it will release its fourth quarter and full year 2021 financial results after market close on March 31, 2022. An investor conference call is scheduled for April 5, 2022, at 10:00 a.m. CDT, to discuss these results and provide further updates. The call will feature President & CEO Jess Jankowski and COO Kevin Cureton. Participants can join the call via U.S. dial-in at 877-312-8776 or international at 408-774-4007. Access to the call will also be available through their website.

Nanophase Technologies Corporation (OTCQB: NANX) has announced the appointment of Ed Sieracki as Vice President of Brand Partnerships and Jennifer Bayon as Vice President of Licensing and Retail Partnerships. These roles aim to enhance customer success and growth among brand and retail partners in response to the increasing demand for Solésence products. Sieracki brings extensive experience from Minerals Technologies Inc., while Bayon has a successful track record from Paris Presents Incorporated. The company has also expanded its team to bolster client service and ongoing GMP efforts.

Solésence Beauty Science has received TGA GMP site clearance, allowing Nanophase Technologies (NANX), its wholly owned subsidiary, to manufacture and market sunscreens in Australia. This long-awaited approval, anticipated for years, enables expansion into a sun care market valued at approximately $120 million USD. CEO Jess Jankowski emphasized the potential for growth in Australia, while COO Kevin Cureton noted an exciting opportunity for globalization and collaboration with brand partners. The approval is a significant milestone for Solésence, enhancing its product offerings in environmental protection technologies.

Nanophase Technologies (OTCQB: NANX) reported a record third quarter with an impressive 80% year-over-year growth. For the nine months ending September 30, 2021, revenue reached $22.1 million, exceeding the full year 2020 revenue by 98%. The Solésence product line saw a remarkable growth of 204% to $13.4 million. Income from operations increased to $2.9 million, with a net income of $2.7 million, or $0.04 per share. The company anticipates continued growth through 2022, bolstered by existing purchase orders worth $27 million.

Nanophase Technologies Corporation (OTCQB: NANX) will release its third quarter 2021 financial results on November 3, 2021, at 3:00 p.m. CDT. This will be followed by a conference call on November 4, 2021, at 10:00 a.m. CDT, hosted by CEO Jess Jankowski and COO Kevin Cureton. U.S. callers can dial 877-312-8776, while international callers can reach 408-774-4007, using conference ID 6190086. The call can also be accessed via www.nanophase.com under Investor Relations.

Nanophase Technologies Corporation (NANX) reported significant growth, achieving 69% year-over-year revenue increase in the six months ending June 30, 2021, totaling $14.2 million compared to $8.4 million in 2020. The company saw triple-digit growth in its Solésence beauty science segment, with revenues hitting $8.8 million, marking a 210% increase. Personal care ingredient revenues were $3.2 million, down 8% year-over-year. Despite a strong first half, demand for medical diagnostics appears to be declining. A net income of $1.4 million was reported, up from $0.4 million in 2020.

Nanophase Technologies Corporation (NANX) announced a remarkable 75% year-over-year growth with $7.1 million in revenue for Q1 2021, up from $4.0 million in 2020. Solésence beauty science sales surged 182% to $4.3 million, making up over 60% of 2020's total revenue. Additionally, advanced materials revenue rose 133% to $1.4 million, driven by medical diagnostics. However, personal care ingredients revenue fell 28%. The company secured over $14 million in purchase orders for Q2 and Q3, indicating strong future demand.

Nanophase Technologies Corporation (OTCQB: NANX) reported a remarkable 35% growth in 2020, achieving a net income of $1 million, or $0.03 per share, compared to a net loss of $3 million in 2019. Notable revenue increases were observed in Solésence products, which rose 263% to $6.7 million, and advanced materials, up 77% to $4.9 million, driven largely by medical diagnostics. The company anticipates continued market acceptance, with $12 million in purchase orders entering 2021. Despite a 30% decline in personal care ingredient sales, overall demand for their innovative products has increased significantly.